Item does not contain fulltextMalignant melanomas are known for their remarkable morphological variation and aberrant immunophenotype with loss of lineage-specific markers, especially in recurrences and metastases. Hot spot mutations in BRAF, NRAS, GNAQ, and GNA11 and mutations in KIT are oncogenic events in melanomas. Therefore, genotyping can be a useful ancillary diagnostic tool. We present one case each of recurrent and metastatic melanoma, both showing histological and immunohistochemical features of solitary fibrous tumor (SFT). Mutational analysis detected BRAF and NRAS mutations in the primary and secondary lesions, respectively. This result confirmed the diagnosis of recurrent/metastastic melanoma
The paper provides a clinical description and analysis of two melanoma cases with mutations in the B...
textabstractBackground Melanoma of unknown primary site (MUP) is not a completely understood entity ...
Primary cutaneous melanoma is a cancer arising from melanocytes in the skin. In recent decades the i...
Purpose. ...
PURPOSEThe prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inc...
We describe a highly unusual case of metastatic melanoma in a 61-year-old female that manifested as ...
Abstract: Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development...
Background: In the context of amelanotic melanoma, little is known on the genetic or molecular backg...
Background: Metastases represent a small percentage of the malignancies affecting the breast, and on...
Diversity between metastatic melanoma tumours in individual patients is known; however, the molecula...
BACKGROUND: Cutaneous melanoma can metastasise haematogenously and/or lymphogenously to form satelli...
Cutaneous melanoma is a disease which results from a complex mixture of various extrinsic and intrin...
Previous studies have shown frequent mutations in the BRAF (V-raf murine sarcoma viral oncogene homo...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The paper provides a clinical description and analysis of two melanoma cases with mutations in the B...
textabstractBackground Melanoma of unknown primary site (MUP) is not a completely understood entity ...
Primary cutaneous melanoma is a cancer arising from melanocytes in the skin. In recent decades the i...
Purpose. ...
PURPOSEThe prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inc...
We describe a highly unusual case of metastatic melanoma in a 61-year-old female that manifested as ...
Abstract: Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development...
Background: In the context of amelanotic melanoma, little is known on the genetic or molecular backg...
Background: Metastases represent a small percentage of the malignancies affecting the breast, and on...
Diversity between metastatic melanoma tumours in individual patients is known; however, the molecula...
BACKGROUND: Cutaneous melanoma can metastasise haematogenously and/or lymphogenously to form satelli...
Cutaneous melanoma is a disease which results from a complex mixture of various extrinsic and intrin...
Previous studies have shown frequent mutations in the BRAF (V-raf murine sarcoma viral oncogene homo...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends,...
The paper provides a clinical description and analysis of two melanoma cases with mutations in the B...
textabstractBackground Melanoma of unknown primary site (MUP) is not a completely understood entity ...
Primary cutaneous melanoma is a cancer arising from melanocytes in the skin. In recent decades the i...